SYNAPCELL ‘s mission is to help identify and qualify the therapeutic potential of molecules, by providing an uncompromising and unmatched service.
Incorporated in 2005, SYNAPCELL has since developed and launched on the market innovative drug discovery solutions based upon integrative electrophysiology markers, animal models and expert knowhow. With their solutions, the potential of a drug is characterized at the very early stages of development and can be compared to the ones on the market.
The Company is actively engaged in the development of new predictive solutions in CNS pathologies, internally or in collaboration with national and international partners – RHENEPI (French, FUI, 2010-13), Neurinox (FP7 European large scale project, 2012-17), COinside (French, FUI, starting autumn 2015).
ZAC ISIPARC - La Bâtie
38330 St Ismier - FRANCE
Date of creation : 2005
Number of employees : 11
+33 (0)4 58 17 15 83
FOLLOW US !
- UroMems Raises €16 Million to Advance Development of Electronic Artificial Urinary Sphincter (eAUS) for Stress Urinary Incontinence
- UroMems Appoints Medical Device Industry Leader Steffen Hovard to Board of Directors
- Commission postpones application of the Medical Devices Regulation to prioritise the fight against coronavirus
By clicking on "Subscribe", You agree to receive the MEDICALPS newsletter and offers every month.
You can easily unsubscribe at any time via the unsubscribe link in each of our emails.
5, avenue du Grand Sablon
38700 La Tronche
Tel. +33 (0)4 76 54 95 63